Reprogramming this axis via kinase inhibitors, BH3-mimetics targeting Bcl-2:beclin-1, or regulation of crucial post-translational events seems to offer a viable way to push GBM cells into irreversible death and enhance responses to current therapies. This evidence concerns the gene BCL2 and glioblastoma.